Clinical trials in Dordrecht – page 7

125 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Dordrecht at a glance

125

clinical trials

Research sites1

Quick filters

125 trials in Dordrecht

Open in trial search

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Stemline Therapeutics Inc.

Contact Research Centre

Acute myocardial infarction

Not recruiting

Study of Modified Anti-Platelet Therapy with Prasugrel, Ticagrelor, and Clopidogrel in Heart Attack Patients Undergoing Complete Revascularization

Registered drugNo placebo

Study of Modified Anti-Platelet Therapy with Prasugrel, Ticagrelor, and Clopidogrel in Heart Attack Patients Undergoing Complete Revascularization

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:SORIN CRM SAS (Microport CRM)

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Study on Iberdomide, Cyclophosphamide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on Iberdomide, Cyclophosphamide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Breast cancer metastatic

Not recruiting

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abelacimab
Sponsor:Anthos Therapeutics Inc.

Contact Research Centre

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abelacimab
Sponsor:Anthos Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Celgene Corp.

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Gilteritinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Myopia

Not recruiting

Comparison of atropine 0.

Registered drugNo placebo

Comparison of atropine 0.

Registered drugNo placebo

The Netherlands

Participants:0–17 years
Substances:Atropine Sulfate
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

Blood Cancer Therapies
Leukemia Treatment
Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

Heart Disease Management
Blood Clot Prevention
Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

Thyroid Disease Management
Hormone Therapy
Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the Netherlands All countries